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A BST R A C T 
 
 Through advancements in biotechnology, scientists now have the ability to genetically 
manipulate living organisms to possess genes from other species. Such techniques have since 
resulted in transgenic animals being created for multiple applications including the observation 
of disease pathways and testing treatments, drug production, food production, creation of organs 
for transplantation, and observation of biological processes. Unfortunately, the act of altering an 
????????? ??????? and then using the animal for testing raises many ethical and legal issues, 
including animal welfare, environmental safety, and public safety. The debates also focus on 
whether these altered animals can and/or should be patented, and whether such patenting helps or 
hinders medical research.  Overall, this project reviews these topics, and the author concludes 
that despite negative connotations, these animals can be extremely beneficial to society in many 
aspects. 
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PR OJE C T O BJE C T I V ES 
 
 The objective of this project was to discuss transgenic animals and their effects on 
society.  Chapter-1 focuses on the specifics of techniques used to create transgenic animals and 
how to screen the animals for the presence of the transgene. The purpose of Chapter-2 was to 
explain the different applications that transgenic animals have been used for, and introduce 
examples of each category. Chapters -3 and -4 concern the ethical issues and legalities, 
respectively, of transgenesis.  The latter two ?????????????????????????????????????????????????????
certain applications should be discontinued, and if it is acceptable to patent animals. 
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C H APT E R-1: 
T R A NSG E NI C A NI M A L T E C H N O L O G Y 
 
 
 Before the advent of transgenic technology, to study genetic changes in animals, 
scientists were forced to induce random mutations in their genome ???????????????????????????????
???????????? ???????????????. But with key advancements in the field of biology in the 1970s, 
scientists were able to genetically modify living organisms purposefully, to give them new 
properties to help society. The purpose of this chapter is to briefly describe the technology for 
creating transgenic animals. 
 
Cloning the T ransgene 
By definition, a transgenic animal is an animal that possesses a foreign gene purposely 
incorporated into its genome (Transgenic Animals, 2011). The first step in creating a transgenic 
animal is to clone the gene that will be inserted in the animal, termed the transgene. The 
breakthrough experiments that allowed manipulating genes included the ability to cut DNA at 
specific sites and the ability to clone it into vectors.  DNA can be cut at specific sequence sites 
using restriction nucleases. These enzymes are naturally used by bacteria to cleave invading viral 
DNA to inactivate it.  Scientists use restriction enzymes to cut DNA at specific sequence sites 
creating a DNA fragment containing a gene of interest.  Alternatively, scientists can amplify 
specific short segments of DNA using polymerase chain reaction (PCR) (discussed later in this 
chapter).  This process was discovered in 1986 by Kary Mullis, who in 1993 earned a Nobel 
Prize in chemistry (Mullis et al., 1986).  In PCR, short primers designed to flank the gene of 
interest are hybridized to the DNA, and a special type of DNA polymerase is used to synthesize 
DNA from the primers.  Another breakthrough technology of t????????????????????????????????????
DNA fragments into cloning vectors, such as plasmid DNAs or viruses.  These vectors are used 
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to amplify the DNA, making thousands or millions of copies of it for later insertion into the 
???????s genome (Charles River Laboratories, 2005). 
?????????????????????????????organism was an E . coli bacterium transformed with plasmid 
DNA (Cohen et al., 1973).  This technology was extended into animals shortly after in 1974, 
with the first transgenic animal, a mouse containing SV-40 viral DNA fragments (Jaenisch and 
Mintz, 1974).  However, the SV-40 transgenes in this case were not actually expressed in the 
animal.  The first transgenic animal expressing its transgene was a mouse containing a cloned 
growth hormone gene under the control of a metallothionein promoter (Palmiter et al., 1982).  
Later, the transgenic techniques evolved into manipulating embryonic stem cells, creating new 
species of transgenic animals other than mice, and infecting embryos with retroviruses.  
 
Pronuclear Microinjection 
????? ???? ?????????? ???? ????? ???????? ??? ???? ??? ??? ????????? ??? ???? ????????? ??????
Currently, there are two main ways for creating a transgenic animal: pronuclear microinjection 
and embryonic stem cell manipulation (Charles River Laboratories, 2005). Depending on the 
??????????????????????????????????????????? ????????????????????????????????????????  
With pronuclear microinjection, female egg donors are given injections of pregnant mare 
serum gonadotropin and/or human chorionic gonadotropin that cause her to release three to four 
times as many eggs (super-ovulate).  The eggs are either fertilized in vitro, or in vivo by males 
(LATG, 2010).  When fertilization occurs in vivo, the fertilized eggs can be taken by euthanizing 
the female and removing her oviducts (Charles River Laboratories, 2005). Eggs taken early in 
development will contain the male and female pro-nuclei that have not yet fused.  The cloned 
transgene solution is microinjected into either one or both of the pronuclei using an extremely 
fine glass pipette (LATG, 2010).  The male pro-nucleus is usually chosen for microinjection due 
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to its slightly larger size and its close proximity to the periphery of the egg.  After the pro-nuclei 
fuse into one nucleus, producing the zygote, the injected embryos are implanted into a pseudo-
pregnant foster mother (Transgenic Animals, 2011). The pseudo-pregnant foster mother 
(recipient female or surrogate mother) is made pseudo-pregnant by either injecting her with 
hormones, or by mating her with vasectomized males which causes a false pregnancy and allows 
the uterus to receive the egg. The process stimulates the reproductive system, preparing the 
???????????????? ???? ???????????????? ???????????????????-pregnant females prepared by mating 
are identified by the presence of a copulatory plug.   
When making a transgenic animal by pronuclear microinjection, the injected DNA is 
????????? ????????????? ????? ???? ????????? ????????which can harm the animal if the insertion 
location inactivates a necessary gene, or if the insertion activates a cancer-causing oncogene 
(LATG, 2010). In addition, the transgene can insert in an inactive area of the chromosome and 
not be expressed, or can insert multiple times in an active area of the chromosome and become 
highly expressed, so founder animals vary widely in their properties.  The inserted sequences can 
vary in length, and may be expressed in either somatic cells, germ cells, or both, but chimeric 
animals are produced less frequently than when manipulating embryonic stem cells.  For these 
reasons, transgenic pups are screened for presence and expression of the transgene (discussed 
below).  F igure-1 shows an approximate timeline for the creation of a transgenic mouse line by 
pro-nuclear microinjection. Overall, it takes around twenty-three weeks to begin a colony of the 
transgenic founder animals.  
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Embryonic Stem Cell Manipulation 
The second main method for creating transgenic animals is by the manipulation of 
embryonic stem cells.  The advantage of using this technique is it allows the transgene to be 
targeted to a specific location by replacing a host gene or host DNA domain with the transgene 
(LATG, 2010).  Embryonic stem cell manipulation, like pronuclear microinjection, begins by 
creating the desired DNA construct, but in this case the construct can contain sequences 
homologous to the host chromosome to facilitate crossing over. F igure-2 shows an example of a 
vector used for homologous recombination.  The vector includes segments of the target 
chromosome (blue in the diagram), the transgene (red), a gene encoding neomycin resistance 
(neor, green), and a gene encoding thymidine kinase (tk, purple).  Note that the regions of 
homology ????? ???? ????????? ??????????? ?????? ???? ?????????? and the neor gene, while the tk 
gene lies outside of the homologous region. Neor inactivates the antibiotic neomycin and its 
analogs like G418.  Thymidine kinase is an enzyme responsible for adding phosphate groups to 
F igure-1: Approximate T imeline for the Development of a T ransgenic Mouse 
L ine Using Pronuclear M icroinjection.  The entire process takes about 23 weeks, 
beginning with the cloning of the transgene in week-1, and the microinjection of 
the cloned DNA into the pro-nucleus in week-2.  (Charles River Laboratories, 
2005) 
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F igure-2: Diagram of Vector C reated for Embryonic Stem Cell M anipulation  by 
Homologous Recombination.  Note that the vector contains regions of DNA 
homologous to the host chromosome (blue), the cloned transgene (red), a neomycin-
resistance positive selection marker (green), and a thymidine kinase negative selection 
marker (purple).  (Transgenic Animals, 2011) 
the drug gancyclovir, thus activating it. These genes facilitate selection of cells that have 
correctly incorporated the transgene (Transgenic Animals, 2011).  
 
The embryonic stem (ES) cells used for this process are taken from the inner cell mass 
(ICM) of a three-day old blastocyst embryo. The blastocyst is created by in vitro fertilization 
(IVF), and then grown 3-5 days to make a hollow ball of cells containing ES cells (LATG, 
2010). At this stage of life, ES cells are called pluripotent. Pluripotent cells have the ability to 
differentiate into any type cell. The ES cells are isolated and grown into an ES cell line, then the 
transgene DNA is introduced by transfection or electroporation (Charles River Laboratories, 
2005). Transfection uses chemical agents to allow the movement of the DNA into the ES cells 
eliminating the problem of negatively charged DNA particles trying to pass through a negatively 
charged or hydrophobic membrane (Promega.com). Alternatively, electroporation involves 
????????????????????????????????????????????????????????????????? ?????????????????????????????????
the DNA to pass inside (Purves  et  al.,  2001).  
Once the DNA has entered the ES cells, homologous recombination recombines the 
transgene with the target location in the host chromosome.  During homologous recombination, 
identical regions in the cloned ????????????????????????????????????????????????????????????????
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and the DNA is replaced (F igure-3).  Culturing the cells in a medium containing the drugs G418 
and gancyclovir will reveal which cells incorporated the DNA.  The incorporated neor gene acts 
as ??????????????????ion ???????.  Cells correctly taking up the transgene will contain neor and 
will be resistant to G418, while cells lacking the transgene and neor are killed by G418 (Charles 
River Laboratories, 2005).  ????????????????????????????????????????????????? ?????????????????
be present in cells not undergoing homologous recombination, but will be absent in cells 
correctly incorporating the transgene by homologous recombination.  So cells correctly 
containing the transgene by homologous recombination will be resistant to both G418 and 
gancyclovir (diagram upper), while cells containing the transgene and TK randomly will be 
resistant to G418 but killed by gancyclovir (diagram lower) (Transgenic Animals, 2011).  
 
 
 
 
 
 
 
 
 
 
 
 
 
F igure-3: Diagram of the Difference Between Homologous 
Recombination and Random Insertion.  Insertion of the transgene 
by homologous recombination (diagram upper) inserts the neor 
gene, but not thymidine kinase.  Random insertion of the DNA 
(diagram lower) brings both neor and TK.  (Transgenic Animals, 
2011) 
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Once ES cells have been identified as correctly containing the transgene, the ES cells are 
injected into the inner cell mass of a blastocyst (Transgenic Animals, 2011), and the embryo 
implanted as described for pronuclear manipulation (LATG, 2010).  Because only the injected 
ES cells contain the transgene and the remainder of the inner cell mass is normal, only some cells 
of the offspring are transgenic.  This creates chimeric animals in which only some tissues are 
transgenic, so these animals need to be further bred with other transgenics to produce fully 
transgenic offspring.  F igure-4 shows a timeline for developing a transgenic mouse by 
manipulating ES cells.  This process usually takes around 27 weeks, which is slightly longer than 
pronuclear microinjection due to the time taken to screen the ES cells prior to injection into a 
blastocyst.   
 
 
 
Both pronuclear microinjection and the manipulation of ES cells have contributed a large 
amount to the efficiency and reliability of creating transgenic animal lines. The evolution of this 
technology has created many opportunities to study the biological universe and continue research 
from medicine to agriculture to industry (Margawati, 2003). Disease models, food sources, and 
F igure-4: T imel ine for the Development of a T ransgenic Mouse by M anipulating 
Embryonic Stem Cells.  The process takes approximately 27 weeks, including the time 
taken to screen the ES cells for the presence of the transgene.  (Charles River Lab, 2005) 
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transpharmers are just a few types of transgenic animals currently being used to further advance 
the field of biotechnology (LATG, 2010). 
 
Identifying T ransgenic Positives 
 The process of making transgenic animals is not efficient, and most pups born are not 
transgenic.  To identify which pups have taken up the transgene in their genomes, they are 
usually screened by polymerase chain reaction (PCR) or Southern blots.  Usually a very short 
section of tail section is cut off or an ear punch taken, and the DNA is isolated by phenol 
extraction.  Crude DNA samples can also be prepared by alkaline lysis, but this process is less 
accurate (LATG, 2010). Other DNA may also be ex????????????????????????????????????????????
hair bulbs. In cases where polymerase chain reaction is used to analyze the DNA only a minimal 
amount of DNA is needed, such as DNA from ear punches.  When Southern blots are used to 
genotype the animal, more DNA is required like with a tail clip (IACUC, 2009).  
 The process of PCR (F igure-5) copies DNA strands in vitro. The first step of the process 
????????????????????????????????????????????????????????????????????????????????????????????????
templates for the copies (diagram, left side).  Every piece of DNA consists of nucleotide bases 
containing adenine, cytosine, guanine, and thymine. Adenine is always paired with thymine, and 
cytosine is always paired with guanine. After separating the original strands of DNA, the primers 
anneal to regions flanking the transgene.  The primers are designed to have sequences 
complementary to domains on each side of the transgene.  The primers allow a special DNA 
polymerase to attach to the DNA and synthesize DNA from nucleotide precursors in the reaction 
tube (diagram, second column). When the DNA strand is complete, the process can be repeated 
to create more copies of the synthesized DNA (diagram, third column).  As the number of cycles 
of DNA denaturation, primer annealing, and stand synthesis continues, the DNA is amplified 
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exponentially.  For example, by the fourth round there are sixteen copies of the DNA region of 
interest (PCR, 1992).  When screening potential transgenic positives, DNA samples amplified by 
the PCR re?????????????????????????????????????????????????????????????????????????????????????????
Screening DNA by PCR is sensitive and fast, but is prone to contamination, so when sufficient 
DNA is present Southern blots are sometimes used. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
F igure-5: Diagram of Polymerase Chain Reaction.  This process is used to amplify 
a segment of DNA containing the transgene.  It can be used to initially clone the 
transgene, or to screen potential transgenic pups.  (PCR, 1992) 
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 When a larger amount of DNA is available, Southern blots can be used to genotype the 
animal (F igure-6). The technique begins by cutting the DNA into fragments with restriction 
endonuclease enzymes and separating them by size using an agarose gel and electrophoresis 
(diagram, upper left). During electrophoresis, a charge is place across a gel, and the DNA added 
to the end nearest the negative cathode.  Because DNA is negatively charged (due to the 
presence of phosphate residues), it moves towards the positive anode.  Smaller fragments move 
faster than larger fragments, so this separates the fragments by size (Cold Spring Harbor Lab). 
The DNA fragments in the gel are then transferred to a membrane (diagram, upper center 
and right), which allows hybridization of a labeled DNA probe complementary to the transgene 
to the membrane. DNA fragments containing the transgene hybridize to the labeled probe, and 
these fragments are visualized using x-ray film or by chemiluminescence (diagram, left, shown 
as a green band (Southern blot, 2009).  DNA samples hybridizing to the labeled transgene probe 
are scored as transgenic positives. 
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C H APT E R-2:   
T R A NSG E NI C APPL I C A T I O NS 
 
 Since the discovery of transgenesis, knockin animals, knockout animals, and animals 
created by random mutation have evolved to assist researchers in many different applications. 
The type of transgene inserted, the type of mutation it may contain, the type of gene promoter 
used to drive expression, and the animal species used depends highly on the scientific concept 
being explored. It is believed that all mammals have approximately 30,000 genes; however, 
????? ????????? ???????? ???? ??????? ????????????????????? ???? ?????????? ????? ??????? ?? ?????????
?????????????????????????????????????????????????????????????????????????????????????????????
organisms began in the 1970s with in vitro manipulation of a bacterium (Cohen et al., 1973), and 
has advanced to make a wide variety of animals, ranging in size and classification from 
mammals, to reptiles and fish). In addition to serving as models of many biological conditions, 
transgenic animals are used for the production of pharmaceuticals in an ani???????????????????????
organs, and increasing food production. This chapter discusses the applications for transgenic 
technology, and provides examples for each application. 
 
Disease Models 
 
 The first use of transgenic animals that will be discussed in this chapter is the disease 
model. Studies performed to observe disease pathways or to screen potential therapeutics are 
typically done by creating transgenic animals and/or gene targeted animals. Developed models 
????????????????????? ??????????????????????? ????????????????????????????????????????????????????
?????????????????????????????????????????????????????????????????????????????????????????????
will be discussed. 
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AIDS Mice 
 
 Human immunodeficiency virus (HIV-1; the AIDS causing virus) was discovered in 
1983 (Barré-Sinoussi et al., 1983), and is a retrovirus that enters human cells with the assistance 
of CD4 receptors (a glycoprotein) and a CCR5 co-receptor on the cell surface of T lymphocytes 
(a type of white blood cell) and deteriorates human immune systems. Early experiments with 
AIDS patients focused on assaying viral plasma load, CD4+ cell counts (and its deterioration), 
and human leukocyte antigens (HLA) to determine key characteristics contributing to disease 
progression (Saah et al., 1998). But in nature, only humans and primates can be infected with 
HIV, and only humans get AIDS.  So scientists needed to develop a better experimental model. 
 To begin the studies, investigators were forced to find a way to overcome the fact that 
mice lack HIV CD4 and CCR5 receptors on the surfaces of their T cells. The original 
experiment, performed in 1988 at the Laboratory of Molecular Microbiology, National Institute 
of Allergy and Infectious Diseases in Bethesda, involved injecting fertilized mouse eggs with the 
entire genetic proviral sequence of HIV (Leonard et al., 1988).  This resulted in thirteen founder 
transgenic mice, none of which developed symptoms of AIDS. However, mating them with 
normal laboratory mice produced offspring that eventually acquired several AIDS-like 
symptoms, including enlarged lymph glands, enlarged spleens, and pneumonia, before they all 
died at twenty-five to twenty-eight days of age. Another transgenic litter consisted of all runts 
that developed a psoriasis-like skin disease. Mice that were sick tested positive for HIV DNA 
while healthy mice did not. Unfortunately, a laboratory accident resulted in all but three of the 
mice dying, so the strain was lost (Weiss, 1988). 
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 In the same year, Joseph McCune at Stanford University School of Medicine developed a 
mouse line containing a human immune system (Namikawa et al., 1988). These mice are now 
termed SCID-hu (humanized severe combined immune deficient mice) or Thy/Liv (thymus-liver, 
pertaining to the human tissue grafted into the mice) (McCune, 1997; Weiss, 1988). To produce 
these mice, they were given severe combined immunodeficiency disease (SCID; a disease in 
which the animal has no B or T lymphocytes) by knocking out the gamma-????????-cell receptor 
that is required for immune system function.  The SCID mice were then implanted with human 
????????????????????????????????????????????????????????????????????????????????????????????????
?????????????????????????????????????????????????????????????????????????????????????????????
tissue from inducing a foreign body immune response, and the engrafted tissue would produce 
human T-cells capable of being infected with HIV (McCune, 1997).  The data indicated that the 
humanized graft survived, and it could be infected by HIV.  Although the mice did not develop 
AIDS symptoms, the model allowed scientists to study HIV cell infection processes.  These mice 
remain as one of the few models to study HIV-1 pathogenesis in the human thymus and T-cells 
in vivo. They also allow investigations into the mechanis??????????????????????????????????????????
Evaluating potential antiviral compounds in large groups of mice contributes to the development 
of preclinical drugs for HIV-1, and the development of gene therapy procedures against the 
disease.   
 More recent studies have been performed with rats, because rat cells contain host proteins 
??????????????????????????????????????????????????????????????????????????????????????????????????
containing the full HIV proviral sequence that expresses a variety of functional viral proteins and 
shows multiple types of AIDS-like symptoms (Reid et al., 2001).  These rodents allow an 
analysis of the interaction of viral proteins with host cell factors. Other HIV infection models are 
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created to express CD4 and CCR5 chemokine co-receptors, and are important for studying the 
pathway of the disease (McCune, 1997). 
 
???????????? ??? 
 
 Alzheimer's disease (AD) is a neurodegenerative disorder first characterized by German 
neurologist Alois Alzheimer almost 100 years ago, and is the fourth leading cause of death in the 
?????????? ?????? ????????????? ????????????? ??????? ????? ???-approved drugs are currently 
available, but they only temporarily treat the symptoms, and are not a cure.  Both sporadic and 
genetic versions of AD exist.  For the genetic versions, mutated genes responsible for early onset 
AD include the ?-amyloid precursor protein (?-APP) gene, presenilin-1 (PS1), and presenilin-2 
????????????????????????????????-APP gene is located on chromosome 21, the PS1 gene is located 
on chromosome 14, and PS2 gene is located on chromosome 12 (Janus et al., 2000). The cause 
of AD is unknown, but appears to involve the production of extracellular deposits of the peptide 
?-??????????-???????????????????????????????????????????????????????????ues in the cortex and 
???????????? ?????? ??? ???? ????????????? ???? ????????? ??? ????????? ??????????????? ??? ?????????
from APP by an abnormal cleavage process catalyzed by beta and gamma-secretase enzymes.  
Other neuro-pathologic features of the disease include the deposits of intracellular neurofibrillary 
tangles (NFTs) comprised of tau protein, decreased synaptic density, and loss of neurons located 
in the basal forebrain (Janus et al., 2000).  Humans and higher primates get AD, but neither is a 
good experimental model, so scientists sought to develop mice that mimic the disease. 
 The first functional AD model was created in 1995 in Worcester, Massachusetts, at WPI 
in collaboration with the former Transgenic Sciences Incorporated (TSI) (Games et al., 1995).  
The transgene inserted into this mouse strain was human APP mutated to mimic an early-onset 
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AD mutation found in an Indiana pedigree (Murrell et al., 1991).  The human APP transgene was 
placed under the control of a PDGF promoter to drive APP expression in the cortex and 
hippocampus, the same regions affected in AD.  The data showed a successful production of 
???????????????????????????????????????????????????????????????????????????????????????????????
al., 1995).  The mice were later shown to have learning and behavioral deficits similar to AD 
patients (Hsiao et al., 1996). 
 Following the construction of the initial AD model, scientists later developed many other 
types of models, from those over-expressing other types of early-onset APP mutations (London, 
Sweden, Baltimore), over-expressing several types of PSEN mutations, or over-expressing beta 
and gamma-?????????? ????????????????????????? ?????????????????????????????????????????????????
???????? ??????????????????????????????????????????????????????????????ought to be one of the key 
initiators of AD (Moran et al., 1995). For instance, a mutation that stimulates the ?-secretase 
enzyme pathway results in over-production of the A?.  In another case, targeting the ?-secretase 
pathway also causes an increase in the abnormal cleavage of APP to produce A?.  A transgenic 
mouse line made by a different laboratory also enhances ?-secretase cleavage, but the mice 
contain all three splice variants of APP (695, 714, 751, and 770 amino acids long) in their 
genomes, similar to that done in the original 1995 AD model (Games et al., 1995). Allowing the 
production of all three APP isoforms by including introns six through eight and the platelet-
derived growth factor ?-chain (PDGF-?) is thought to be important to AD (Janus et al, 2000).  
The increased A? deposits can also result from AD mice containing mutations in the PS1 gene, 
which affect the gamma-secretase pathway (Duff et al., 1996). 
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Oncomice & Chemoprevention Models 
 
 There are two types of transgenic animals currently used in cancer studies: oncomice and 
chemoprevention models. Oncomice are genetically engineered to express cancer causing genes, 
or oncogenes, in order to study carcinogenesis (e.g. events leading to loss of cell cycle control 
and tumorigenesis) (Hanahan et al., 2007). On the other hand, chemoprevention models are 
created to study ways to reverse, suppress, and prevent cancer development (Alexander, 2000).  
 ???? ???????? ?????? ?????????? ???? ???????????? ??? ????? ??? ??????? ?????? ??? ????????
University, in collaboration with Dupont (Stewart et al., 1984).  The transgene inserted into this 
mouse line was c-Myc oncogene under the control of a mouse mammary tumor viral promoter 
that expressed the oncogene only in mammary tissue.  The mouse was patented in the U.S. in 
????????????????????????????????????????????????????????????????????????-4) (Leder and Stewart, 
1984).  Based on previous attempts at constructs with the Mt1 (mouse metallothionein-1) gene 
promoter incorporated with the v-Src oncogene, the scientists tested a Mt1-Myc complex and a 
E?-Myc complex, expecting to mimic the chromosomal translocation characteristic of human B-
cell lymphomas.  The Mt1-Myc consisted of the Mt1 promoter gene and the Myc oncogene, and 
was predicted to cause broad expression of Myc. On the other hand, the E?-Myc consisted of the 
immunoglobulin enhancer (E?) with the Myc gene. Mt1-Myc transgenic mice did not end up 
developing any tumors, however, the E?-Myc mice showed development of pre-B-cell and 
mature B-cell lymphomas (Hanahan et al., 2007).  
 Mouse models used to study cancer pathways can also be used to study potential chemo-
preventative agents. p53-KO mice have been developed in which the p53 tumor suppressor gene 
has been knocked out (Harvey et al., 1993). Protein p53 normally functions to help repair DNA 
mutations as they form.  If it is knocked out, the mutations remain unrepaired, so cancer forms. 
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In one chemoprevention study, it was found that this particular type of knockout causes a type of 
tumorigenesis that is greatly affected by calorie restriction, and giving the mice dehydro-
episandrosterone and 16-?-fluoro-5-androsten-17-one compounds caused reduced food intake 
and most likely delayed tumor development due to glucose-6-phosphate dehydrogenase 
inhibition and less DNA synthesis (Alexander, 2000).  
 
T ranspharmers 
 
 ???????????????????????????????????????????????????????????????????????????????????????
pharmaceutical protein drug in large quantities in the milk, blood, or urine (Biotechnology, 
1995). The aim of transpharmers is to not only provide a high level of product, but to also 
provide a cost effective and safe way to produce drugs. Early methods to isolate biologically 
active human proteins would either purify the protein from human cadavers, risking viral 
contamination, or produce the drug in mammalian cell culture system. Although mammalian cell 
cultures are safer, the amount of drug that can be produced is significantly lower (Brink et al., 
2000).     
 Since the development of the first transpharmer mouse in 1987 that produced a human 
clot dissolver drug tPA in its milk (Gordon et al., 1987), milk has remained the most popular 
production fluid for transpharming.  To express a protein in milk, the transgene must be under 
the control of a milk protein promoter, such as casein, beta-lactoglobulin, or whey acid protein.  
Drug development in milk has increased in popularity because transgenic animals can produce at 
least one gram of therapeutic protein per liter of milk, which in turn reduces the number of 
animals required (Brink et al., 2000). Producing in milk does not require euthanasia of the animal 
??? ??????? ???? ?????? ?????? ????? ????? ????? ?????????? ??? ???????? ???????? ???????? ???? ????????
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plasminogen activator, a clot dissolver), human factors VIII and IX (blood clot treatments), 
lactoferrin (infant formula additive), CFTR (cystic fibrosis transmembrane conductance 
regulator), and hemoglobin (blood substitute for human transfusions) (Biotechnology, 1995).  
More recently, ATryn® (anti-thrombin blood thinner) has also been transpharmed, and in 2008 
????????????????????irst FDA-approved drug for use in humans (discussed below). 
 
Transpharmer Mice 
 
 The first transpharmer animal made was a mouse that expressed the human tissue 
plasminogen activator (tPA) protein in its milk (Gordon et al., 1987). Research performed in 
1988, tested the levels of the protein transcripts present in the mammary gland of lactating mice. 
The mice were expected to express the gene and secrete the product in the milk. The construct in 
question, named WAP-tPA, hybridized tPA with the promoter region of whey acidic protein 
(WAP). The results showed that tPA was detected in the milk and was biologically active. A 
statistical analysis showed that significant differences in the degree of transgene expression 
occurred as a consequence of random insertion into the genome of various transgenic lines. It 
was also noted that because the concentrations of the protein increased in the mammary gland 
but did not increase in the sublingual gland, tongue, or kidney during lactation, the expression 
was limited to the mammary gland (Pittius et al., 1988). 
 
Transpharmer Cows & Herman the Bull 
 
 Transpharming is not limited to mice.  In 1989, a bull was created to produce lactoferrin 
??? ????????? ?????????? ??? ????? ??????????????????? ?????? ??????????? ?????? ?????????????? ?howed 
lactoferrin gene integration, and his female offspring transpharmed the drug in their milk. Since 
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then, other cows have been created by gene-targeted expression in the mammary gland, using 
promoters such as ovine ?-lactoglobulin, caprine ?-casein, murine whey acidic protein (WAP), 
and bovine ?S1 casein. The transgene used to create Herman used the ?S1 casein promoter and 
the cDNA encoding human lactoferrin. More recent studies have shown that the use of cDNA in 
contrast to using the entire gene (which includes exons and introns), is not as effective as using 
????????????????????????????????????????????????????????????????????????????????????????????????
grams per liter of milk as his transgene was a cDNA (Brink et al., 1999).  
 
Transpharmer Goats 
 
 Transpharmer goats manipulated to produce ATryn®, anti-thrombin blood thinner 
protein, were the first transpharmed product approved by both the Food and Drug Administration 
(FDA) and the European Medicines Agency (ATryn®, 2008; Ledford, 2006). Before being 
approved, refinements needed to be done to increase the percentage of successfully transpharmed 
animals. One breakthrough study used the Gibbon ape leukemia virus (GaLV) retroviral vector 
to insert reporter genes into the mammary epithelial cells of goats. The experiment resulted in the 
secretion of human growth hormone (hGH) in the milk of the animals at high levels. Archer and 
colleagues (1994) observed that each of the goats had different levels of expression of the growth 
hormone, and the general trend decreased and eventually reached a plateau. The group concluded 
that the high level of protein on day-1 of lactation could have been due to a number of things 
including: hGH from the viral infusate still present from the injection on the previous day, 
mRNAs being more largely present on the first day, and/or long terminal repeat (LTR) 
stabilization. Finally, it was found that it is possible to introduce a drug to the mammary gland 
via retrovirus and have it be successfully expressed over a long period of time. Because of the 
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poor ratio of mammary cells to virus particles, it was proposed that improving the ratio by 
increasing the amount of virus, as well as altering the timeline and frequency of the viral 
treatments could lead to an improved protocol for creating transpharmer animals (Archer et al., 
1994). 
 
Xenotransplanters 
 
 Xenotransplantation is the procedure in which a nonhuman animal source is the donor of 
cells, tissues, or organs meant to be transplanted, implanted, or infused into a human. The 
concept is being explored as a potential alternative to help solve the organ shortage for patients 
in need of vital organs (U.S. FDA, 2010). Statistics in 1999 showed that only 2,300 out of the 
40,000 people that needed hearts got one (Mooney et al., 1999). As of 2010, the numbers 
indicated that 10 patients die every day waiting for a transplant organ (U.S. FDA, 2010). 
Xenotransplanters are closely related to current methods of tissue regeneration that scientists are 
??????? ??? ???????? ???? ????-the-??????? ???????? ????????? ??????? ?????????? ?????? ????? ??? ??????? ??
scaffold of biodegradable polymers that can allow cell replication so when the polymer breaks 
down, the neo-organ (man-made organ) will remain as a natural product (Mooney et al., 1999).  
 A large problem with engineered tissue and organs from xenotransplanters is to overcome 
the human immune response. Since the first successful xenotransplantation in the 1960s, when 
chimpanzee kidneys were transplanted into 13 patients (Reemtsma et al., 1964), chimpanzee 
kidneys, hearts and a baboon heart have been tested in humans, and both eventually failed. The 
monkey donors were then abandoned, and scientists decided to try using pigs hoping that their 
organ size and function is similar enough to human anatomy to work. Currently, pig heart valves 
are routinely used worldwide. The ability to use porcine heart valves lies in the fact that they are 
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mostly connective tissue and do not cause immune rejection.  Unfortunately for pig organs, a 
porcine sugar, ?-galactose (?-gal), on the surface of pig cells causes rejection when antibodies in 
the human donor attack the sugar. Although some people believe that there is more than just the 
?-gal involved with rejections (e.g. the host attacks the porcine blood vessels as well), scientists 
???????????????????????????????????????????????????-galactosyl-?????????????????????????????-gal 
on the cell surface (Lai et al., 2002).  January of 2002 marked an advance in preventing immune 
?????????????????????????????????????????????????????????-galactosyl-transferase.  Although this is 
a good start, the pigs still contain one intact allele for the enzyme, so future experiments need to 
be performed to knock out the other allele (Couzin, 2002).  
 
T ransgenic Food Sources 
 
 Another application of transgenic animals resides in the agriculture and food industry. 
There are currently no transgenic animals commercially produced and sold for food purposes, 
although the methods for production are still being tested to eventually allow it. The 
improvements targeted in transgenic food animals include more efficient meat production and 
higher safety in areas such as disease and/or parasite resistance, increased growth rate and feed 
conversion efficiency, as well as increased nutrition (Harper et al., 2006). As of 2010, the FDA 
was close to approving a genetically modified Atlantic Salmon containing a growth hormone 
(explained below) (Marris, 2010). Transgenic pigs and other livestock are also being tested for 
their ability to produce food, however, those experiments are still under development (Harper et 
al., 2006). 
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Superfish 
 
 ???? ?????? ????? ??????????? ?????????????? ??????????? ???? ???????? ??? ???????? ?? ??????
growth hormone transgene under the control of the mouse metallothionein promoter (Devlin et 
al., 1997). Created by injecting the DNA into the germinal disc of a goldfish embryo, the fish in 
general prove to be easily manipulated due to the large number of gametes they produce, and 
their eggs are fertilized outside the body so re-implantation is not necessary (Harper et al., 2006). 
The so-called Atlantic salmon superfish were further developed by Aquabounty Technologies, 
whose headquarters are located in Waltham, Massachusetts (Aquabounty, 2012), and are the 
closest animal to being approved by the FDA. The fish grow twice as fast as the non-transgenic 
salmon, and some strains now include the gene for Chinook salmon growth hormone and its 
regulatory sequences. Chinook salmon grow throughout the year, allowing the altered Atlantic 
salmon to do the same and grow to be twice as large as the normal Atlantic strain (Marris, 2010). 
 
Superpig 
 
 The use of growth hormone transgenes in pigs does not tell as nice a story as the use of 
similar genes in fish.  ??????????????????????????????????????????????????????????????????????????
their enlarged size, were created in 1988 using pronuclear microinjection (Vize et al., 1988). The 
transgene construct introduced to the fertilized eggs contained a porcine growth hormone (pGH) 
gene fused to the human metallothionein-IIA promoter (hMT-IIA) to ensure the transgene was 
expressed in a wide variety of tissues.  Only one of the pigs successfully expressed the transgene 
and grew faster than the other pigs. Other littermates were found to contain the transgene in their 
genome, but did not express it, and two of the pigs passed the transgene to their offspring. It was 
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found that the pig that grew faster had the transgene integrated randomly and none of the 
resulting growth characteristics caused health problems (Vize et al., 1988). 
 A subsequent study done the following year in 1989 engineered pigs to contain either 
human or bovine growth hormone genes under the control of a mouse metallothionein-1 
promoter (Miller et al., 1989), and although these initial superpigs did not appear to have any 
size benefits, they were found to have leg problems and heart problems. Leg problems were 
thought to result from the skeletal system not being strong enough to withstand the extra weight 
of the superpig. Similarly, the cardiovascular system must also be able to handle the weight of 
the pig, causing heart failure in early m?????????????????????? 
 
T ransgenic Biological Models 
 
 ???????????? ?????? ??????????? ??????? ????? expressed its transgene was not engineered to 
provide a direct benefit to mankind by making a disease model or by transpharming a life-saving 
drug.  Instead, it was a mouse engineered to contain a growth hormone gene under the control of 
a metallothionein promoter to determine whether a biologically active product (growth hormone) 
could be produced by transgenesis (Palmiter et al., 1982). Different from food source 
transgenesis, where the animals size are meant to provide better food supply, supermouse was a 
biological model intended to aid our understanding of growth hormone fusion genes and how 
foreign genes are regulated in vivo (Palmiter et al, 1982).  
 Since the landmark 1982 transgenic animal experiment, other biological models have 
been created to aid our understanding of the consequences of knockout and knockin animals.  As 
???????????????????????????????????????????????????????????????????????????????????? over 5,000 
different strains of knockout mice. The aim of the project is to create different transgenic mouse 
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lines missing a specific gene by stem cell manipulation, and then observe the effects on over 
20,000 mRNAs and proteins in the mouse body by hybridization arrays.  Researchers will also 
observe the visible phenotypes on anatomy, physiology, development, behavior, and disease 
traits in these mice to help understand the roles of each gene throughout the life cycle. It is hoped 
that the project will be complete by the end of 2016 (News of the Week, 2011). 
 
Doogie the Smart Mouse 
 
 ?????????????????????????????????????????????????????????????????????????????????????
specific type of receptor in the brain acts as a switch for memory formation (Tang et al., 1999). 
The N-methyl-D-aspartate (NMDA) receptor binds glutamate in the brain, and is thought to help 
regulate learning and memory formation. The NMDA receptor is composed of two subunits; the 
NR1 subunit is required for function, while the NR2 subunit is a regulatory subunit and varies 
depending on the developmental stage of the animal.  The NR2B subunit predominates when 
mice are young, and learn more easily, so the experiment was designed to determine whether 
over-expressing the NR2B subunit can facilitate learning and memory.  The data indicated that 
over-expressing NR2B in the cortex and hippocampus caused an increased activation of the 
NMDA receptors, and increased learning in memory and behavioral tasks, compared to normal 
mice (Tang et al., 1999). 
 
Youth Mouse 
 At the Weizmann Institute of Science in 1997, transgenic mice were created that lived 
longer than their wild type parents. The mice were designed to over-express urokinase-type 
plasminogen activator (uPA) in the brain. Results of the study showed that the mice consumed 
less food, grew less, gained less weight, and had longer lives. They also had lower blood sugar 
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levels, fewer pups, and less births. It is thought that the lifetime of the mice was extended 
because the uPA over-expression prevented atherosclerosis that is common in aged animals 
(Miskin et al., 1997). 
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C H APT E R-3: 
T R A NSG E NI C E T H I CS 
 
 
As is the case for experiments involving any animals, studies using transgenic animals 
pose problems from the public. Many ethical issues on animal research originate from the late 
1960s, ????? ???? ????? ????? ????????? ????? ????????? ?????? and sold to research companies 
(Cowan, 2010).  Although transgenic animal research has provided technologies that allow 
studying disease formation or testing potential cures, producing life-saving medication, 
providing organs for transplant, or producing food sources to aid a starving planet, the potential 
for abuse of these animals is apparent in each category.  The purpose of this chapter is to discuss 
transgenic ethics and whether these animals should be created, by weighing the benefit of 
transgenic animals against animal welfare issues.  Because the benefits and animal issues vary 
considerably, each category must be discussed separately. 
 
Introduction to Animal E thics 
 
There are three ethical approaches that can be used to determine whether a particular 
animal experiment is cruel. The utilitarian approach is based on the opinion that animal welfare 
creates the standard to deem an ??????????? ???????? or ????ng???Using only this standard, if 
human or animal welfare is enhanced, it might be justified regardless of the proposed experiment 
itself. However, it would eliminate an experiment that might produce a life-saving vaccine if it 
harmed a few mice.  This creates the idea that animals matter morally completely equal to 
humans (Almond, 2000).  
In 1991, Robin Attfield proposed an ethical solution where moral standing is different 
from moral significance (Attfield, 1991). Now called the rights approach, it is centered on the 
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idea that although animals matter, it can be supported to sacrifice them at the benefit of a 
superior being like humans (Attfield, 1991; Almond, 2000). The final concept, the virtue 
approach, states that objects and creatures were mean????????????????????????????????????????????????
So, if an animal was made for testing, then that is what shall happen to it (Almond, 2000).  
In transgenesis, since the animals are not only tested, but also genetically altered, the 
ethics involved with them is more complex than with an animal solely used for testing. Brenda 
???????????????????????????Health, Risk & Society Journal focuses on the issue of how animals 
are treated individually, although newer issues involve the treatment of the species as a whole. 
One side of the argument is that humans have been genetically modifying animals since they 
found it possible to breed dogs and farm animals to better suite their owner. With transgenic 
animals, the problem is not just the genetic modifications, but the acceleration of creating them 
using genetic engineering, and their impact on the environment, economy, and health and safety 
of both animals and humans (Almond, 2000).  
In terms of animal well being, genetically altered animals may be discussed ethically by 
two different aspects of the experiment: first, how they are created, and second by the amount of 
pain and distress the animal endures due to the application. As introduced in Chapter-1, there 
are two main techniques used to create transgenic animals: pronuclear microinjection, and the 
manipulation of embryonic stem (ES) cells. The main difference between the two is that 
pronuclear microinjection integrates the transgene randomly in the host genome, while ES cell 
manipulation allows gene targeted insertion. If the transgene insertion is random and the gene is 
incorporated in a spot that allows birth of the pup, then the mutation has a large range of possible 
effects on the living animal. If the transgene inserts into an inactive region of the chromosome, it 
might not induce ???????????????????????????????????????????????????????????????????????????????
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it could inactivate a required gene or activate an oncogene to cause illness or even death. 
Embryonic stem cell manipulation allows gene targeting, so the direct effect of the transgene is 
known prior to incorporation into the genome (LATG, 2010). The use of ES cells themselves, 
however, have developed an entirely individual ethical debate, since the cells are pluripotent, 
meaning one could potentially create any adult tissue once the cells begin differentiating 
(Charles River Laboratories, 2005). Because of the potentially surprising conditions that could 
arise with using either transgenic technique, it is up to the principal investigator (PI) leading the 
research, and the ???????????????????????????????????????????????????????????????????????????????
characteristics to ensure humane care of the animal. This way if necessary analgesics or 
euthanasia is required, it can be administered at an appropriate time (LATG, 2010; National 
Research Council, 2011). 
One commentary, written by David Porter in 1992, proposes a scoring system similar to 
the system determined by IACUC committees to place a grade on how humane the study is. The 
categories considered involve the potential benefit of the experiment, the expected amount of 
pain, and the duration, number of animals, and quality of the experiment.  Each of these features 
would be experiment specific, while others are more dependent on the application (Porter, 1992). 
???? ????????? ???? ????????????? ????? ??? ?????? ?? ??????????? ?????????????????? ???????? ??? ????
different than for a transpharmer animal.  The remainder of this chapter will focus on the 
different ethical problems associated with specific transgenic examples. 
 
Disease Model E thics 
 
 Because disease models are created to study sickness and disease, they are a part of a 
large number of ethical debates. The main discussion involves the induced pain and/or distress in 
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the animals. Sources such as Recognition and Alleviation of Pain in Laboratory Animals, are 
helpful for determining and controlling pain and distress (NRC, 2009). It is up to the veterinarian 
to recognize when treatment is necessary. Treatments depend on the species, age, degree of pain, 
and length of the study. Often times, with disease models, the experimental endpoint has to be 
the same as the humane endpoint if there is vital information to be determined post death 
(National Research Council, 2011). 
In this category, the health and safety of humans may also be of concern since 
investigators are in direct contact with animals that could potentially pass a disease on to humans 
(Almond, 2000). Of the diseases discussed in this project, the most risky model would be the 
AIDS mouse since the disease could, in theory, be transmitted by ?????????????blood. In reality, 
the chance of human infection is low since HIV mice do not produce infectious HIV virions in 
large quantity, but scientists must always remain vigilant for potential transmission. Moreover, 
as long as people follow rules and wear the proper personal protective equipment (PPE), the 
likeliness of contracting any disease is very low. Environmental and economic impact is not 
usually of concern with disease models, given the animals are not freed into the wild, and 
although valuable, the personal investigators budget should be negligible in comparison to the 
affect of experiments involved with the U.S. Department of Agriculture (Almond, 2000). The 
rest of this section will focus on the three disease model applications discussed in Chapter-2 
(AIDS mice, Alzh????????????????????????????????????????????????????????????????????????????
traits versus the potential benefits of each model. 
 
 
 
 
 
 
 39 
AIDS Mice 
 
Any model involved with AIDS is extremely valuable because in nature only humans and 
chimpanzees spread HIV, and only humans get AIDS.  SCID-hu mice (introduced in Chapter-2) 
benefit the study of HIV-?? ???????? ????? ???? ???? ??? ???? ???? ????????? ??? ????????? ???? ??????????
effects on human thymopoiesis in vivo. Studies involved with differential HIV-1 pathology are 
not possible in humans, therefore, any model that provides key information on T-cell turnover 
and infection is important (McCune, 1997). 
Despite their benefits, SCID-hu mice have a significant downfall. Since fetal human 
organs are implanted into the mice, the physiology may not be fully accurate in analyses meant 
for adults. The implanted human thymus tissue differentiates into the main cellular reservoir for 
HIV (T-cells), but HIV cannot infect the surrounding mouse tissues; so the model cannot be used 
to assay HIV spread. Also, a mouse environment housing human organs may result in 
insufficient functionality of the human cells. However, in some instances there is the reverse 
where the mouse cells lack functionality. Transgenic HIV mice are so dissimilar in comparison 
to humans that they are not expected to be used in vaccine studies, but are of general interest 
because of the ability to analyze infections with HIV (McCune, 1997). 
 Since AIDS is a disease that essentially destroys the immune system, it is possible that 
the animals used for testing are expected to endure pain and sickness at some point during the 
study. The main ethical question for this model is not only what is the expected degree of pain 
but can the ????????????????????????????????????????????????????????????????????????????????can be 
determined only by further analysis. 
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???????????? ??? 
 
 ???????????????????? ?????????????????????????? ?????? ????????????? ?????????? they have 
many downfalls. AD is a very complex disease, and has many criteria that makes transgenic 
testing very difficult on a single model with a specific transgene (Janus et al., 2000). There are 
currently three different genes believed to contribute to AD, and techniques for making 
transgenic animals do not make it easy to make an animal with a triple mutation to study the 
effects simultaneously (Duff et al., 1996). This also contributes to the fact that studies testing 
????????????????????????????????D) may not provide help for the sporadic form of the disease. 
On top of this, the behavioral studies in mice must be analyzed to support their reproducibility 
(Janus et al., 2000). Positively speaking, any study currently being performed to observe AD 
pathway is bringing biotechnology one step closer to finding the ideal model to mimic symptoms 
and help develop preventative measures against the disease (Janus et al., 2000; Moran et al., 
1995).  In spite of the fact that no current AD model fully mimics the disease, the current partial 
models have at least provided a means for testing key theories in AD research (i.e. does the 
amyloid-beta neurotoxin (encoded by the AD mouse) really initiate AD, and can behavior 
improve after removing the amyloid-beta toxin). Two separate studies have proven that 
production of A? is sufficient for initiating AD (Games et al., 1995) and removal of brain A? 
can improve animal behavior (Morley et al., 2002).  
 In terms of pain, AD mice are not expected to experience physical pain due to illness, but 
they risk the possibility of having high stress and anxiety levels (Moran et al., 1995; Janus et al., 
2000), although these symptoms are not present in all the models. Stress is indicated in mouse 
studies largely by either reduced activity and neophobia, or boredom shown with consistent 
circling. If the mice are going to experience pain it would be due to seizures that are often caused 
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by stress or aggressiveness which would cause pain if the mouse was fighting with its cage mates 
(Janus et al., 2000). However, these symptoms are not characteristic of all models, and can be 
reduced with correct husbandry and environmental conditions as with any laboratory animal 
(National Research Council, 2011).  
 
Oncomice & Chemoprevention Models 
 
 According to the American Cancer Society, more than 1.6 million new people are 
expected to be diagnosed with cancer in 2012, and almost 12 million people will be diagnosed 
with cancer at some point in their life (American Cancer Society, 2012). This high statistic 
makes cancer models extremely valuable. Since there are so many different types of cancer, each 
model needs to be approached differently.  Although there is not a singular model demonstrating 
all types of cancer, current models have evolved to more accurately mimic specific tumors in 
organs. Early cancer studies were done by transplanting tumors under the skin of immune-
deficient mice. But these models could not fully imitate the disease. Lacking in the transplant 
models but important in cancer studies are: benign premalignant tumor progression, significant 
histological traits, prediction for therapeutic benefits, and shortcomings of previously tested 
drugs (Hanahan et al., 2007). 
As concluded by Jan Alexander, every mutation being studied provides a little more 
information towards the cure (Alexander, 2000). For instance, mutations in the p53 tumor 
suppressor gene (targeted in the p53-KO mouse), have been found to be involved with over 50% 
of all known human tumor types.  However, there are several forms of cancer that are not 
affected by loss of p53 function (Harvey et al., 1993). Generally, the ethical issues in tumor 
models are found with the discussion of physical pain that the animal has to endure. The tumor 
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may not only cause direct pain, but could cause physical impairment if the tumor is located next 
to a leg and grows to a significant size. Such problems must be closely reviewed by the IACUC 
committees to determine both the experimental endpoint and humane endpoint (National 
Research Council, 2011). 
 
T ranspharmer E thics 
 
 The ultimate goal with transpharmer animals is to create animals not physiologically 
affected by the drugs they produce.  ??????????????????????????????????????????????????????????
and Drug Administr????????????????????????????????????????) prior to human use of the produced 
therapeutic. Due to the fact that the transpharming application must be adequate for consumer 
use, both animal and human safety must be considered. Specific drugs have already proven to be 
safe for both animals and humans. For example, in 2008, Genzyme Transgenics Corporation 
(GTC) received U.S. FDA approval for human use of its anti-thrombin blood thinner drug 
ATryn® transpharmed from goats?????? (ATryn®, 2008). Other proteins such as lactoferrin and 
tissue plasminogen activator (tPA) can be expressed in the mammary gland, with no observable 
effects on the animal, while remaining biologically active in humans. Production of 
pharmaceuticals in the milk has shown to be more humane towards the animals than production 
in blood, since the former does not interfere with the animal?s health. On the other hand, proteins 
such as hemoglobin are ?????????????????????????????????????????requiring controlled bleeding or 
euthanasia to obtain the drug (Biotechnology Information Series, 1995). Purification from blood 
also risks viral contamination, endangering humans with the potential of infection with animal 
viruses (Brink et al., 2000; Almond, 2000). Also, since the drug is expelled f?????????????????
body there is a risk of allowing the drug to enter the environment by either consumer or producer 
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error (i.e. if the milk is dropped). This has the possibility of creating antibiotic-resistant bacteria, 
increasing human risk of sickness and environmental problems (Almond, 2000). 
 The main purpose of these transgenic farm animals is to provide a cheap alternative for 
large scale drug production (Pittius et al., 1988). Early cell culture systems are safer than 
purification from cadavers, however, the few number of animals needed to produce a large 
quantity of drugs provides a cost effective strategy (Brink et al., 2000).  Ongoing problems 
include the low transgenic success rates with large animals due to the low number of embryos 
that can be transferred, and the long time periods involved with making large animals transgenic 
(Brink et al., 2000), which has proven to increase the cost in advancements (Biotechnology 
Information Series, 1995).  Unfortunately for small farms, once the application is approved, large 
farm enterprises will be able to adopt the system, causing traditional farming to lose value 
(Mepham, 1994; Almond, 2000).   
 
Xenotransplanter E thics 
 
 Ethically speaking, xenotransplantation is frowned upon due to the bad image these 
animals have been given for this application.  Some people believe that this type of application 
has turned animals into tools rather than living things (Mepham, 1994). According to Juan 
Correa, speaking in terms of religion and creation, the animals have their own value and they 
were brought to this earth to serve man. Looking at it from the human standpoint, however, 
religious issues state that taking organs from non-humans interfere with the order of creation 
(Correa, 2001). On the other hand, the concept of xenotransplantation has opened many doors to 
solving the organ shortage problem. Couzin presents the argument that even if long term survival 
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with a xenotransplant is not possible, creating organs that can be used will at least increase the 
amount of time the person has to find a permanent human organ (Couzin, 2002).  
Since xenotransplanters are created for organs that can be put into a human body, the 
animal has to be designed so that the donated organ will not cause an immune response in the 
recipient human. Not only do humans have to concern themselves with the natural immune 
response of having an animal organ in their body, but they also must think about any diseases 
that may be passed between species. For example, all pigs have porcine endogenous retrovirus 
(PERV), but the problems the disease may cause in humans are not known. Problems like this 
most likely would occur with diseases that appear harmless to pigs. When the organ is implanted 
into a different species, if the disease has not been studied, there is the possibility of something 
being harmful to the recipient. Because of these risks, the FDA is extremely stringent on 
allowing clinical trials to test the transplants (Couzin, 2002). When the FDA finally approves a 
xenotransplantation model, large farms may begin threatening the economics of smaller farms 
(Mepham, 1994). 
 
Food Source E thics 
 
 The aim of transgenic food sources is to increase production and quality of food from 
animals. Like xenotransplanters and transpharmers, the issues largely depend on approval by the 
FDA since the animals would be consumed (Harper et al., 2006). People believe there are two 
main benefits to increasing growth hormones in farm animals. First, faster growth results in 
quicker slaughter of the animal, thus decreasing the amount of saturated fats in the meat which 
should be avoided in human diet. Also, if the animal is larger, the increased amount of meat will 
require less animals overall. This not only benefits animal welfare but proves to be 
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environmentally friendly. Utilizing the animal resources for food, can decrease the 
environmental impact of production systems and slaughter houses, while increasing economic 
risks for small farming (Mepham, 1994). 
 But the debate of killing and consuming animals for human consumption has become an 
ever-growing debate, because food production raises the issue of the treatment of such animals. 
With genetically engineered animals, however, the welfare of the animal could directly affect 
humans that consume ????????????????????????????? ??? ????????????????????????????????????, 1997), 
are of highest concern when it comes to the welfare of both humans and animals (Mepham, 
1994). The Beltsville Pigs were produced to increase their growth for food production, and the 
size ended up affecting every organ system in the animals. Their bodies could not handle the 
weight; as a result, they contracted diseases such as pneumonia, arthritis, and peptic ulcers 
(Pursel et al., 1997). As with non-genetically engineered animals, if an animal previously had an 
illness that could be passed to humans, it would pose a very dangerous risk when consumed. One 
may believe that this could be easily solved by giving the animal antibiotics, although, then 
scientists risk creating antibiotic-resistant bacteria (Mepham, 1994).  
 
Biological Model E thics 
 
 Unlike disease models and the rest of transgenic applications described in this review, 
there is no medical life-saving goal for biological models, except to increase our understanding 
of specific genes. Since biological models are not created to interact with or be consumed by 
humans, there are no FDA regulations involved. This means that ethics mainly revolve around 
the animal?s welfare. As with any other knockin or knockout animal, when the gene is 
deactivated there will be a lack of its protein product in the animal, while gene over-expression 
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will increase the protein product. The aim of biological models is to see what happens as a result 
of over-expression or under-expression of the transgene. Unfortunately, until tested, the mutation 
could potentially be extremely harmful to the animal. Where, on the other hand, it could be 
harmless (LATG, 2010). For instance, youth mouse (described in Chapter-2) was essentially no 
different from a non-transgenic mouse, and had no health problems. They were found to be 
smaller and had less breeding potential, but overall were not sick or harmed by the over-
expression of urokinase-type plasminogen activator (uPA). They just displayed increased 
learning and memory (Miskin et al., 1997). As with youth mouse, Doogie the Sm????????????
welfare was unaffected by overexpression of the NR2B subunit of the N-methyl-D-aspartate 
(NMDA; Tang et al., 1999).  
 
?????????Conclusion on T ransgenic E thics 
 
 Advancements in transgenesis have revealed many controversial opinions regarding 
human health, animal welfare, and the impact on the environment and economy. After 
evaluation, the author has concluded that in a majority of cases, the benefits of these animals 
outweigh the potential problems. Ongoing refinements of the technology, continue to help 
scientists minimize animal suffering while maximizing human benefits.  Over the years, each 
improvement pushes science one step closer to achieving a significant lifesaving goal. For 
instance, the human genome project has resulted in significant improvements to the cost of 
accurately sequencing large segments of DNA, and this now makes it easier to accurately assay 
transgene insertion sites. Knowing the human genome has allowed scientists to target all 20,000-
25,000 genes responsible for human bodily functions, ranging from growing and learning to 
suppressing tumors (Human Genome Program, 2012). This has led to the revolution of 
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understanding disease pathways and developing models and treatments for the diseases. 
Although public perception is that genetically modified animals are treated poorly, books (i.e. 
The Guide; National Resource Council, 2011), laws (i.e. The Animal Welfare Act; U.S. 
Congress, 1966), and organizations (i.e. IACUC; IACUC, 2005) (discussed in Chapter-4) have 
been developed to regulate animal use in experimentation and help ensure animals are treated 
humanely. Each transgenic application is widely different, though, causing IACUC committees 
to analyze each proposed study individually. Similarly, people who argue an opinion on the 
technology must do so in view of all the issues from an educated point of view.  
 With transgenic disease models, depending on the disease modeled and how accurate the 
model is, they may endure pain and stress. Despite this, when looking in terms of the future of 
the application, the decreased animal welfare is worthwhile. First, the animal is sick, but 
protocols require relief and treatment of sick animals when observed. As long as standard animal 
husbandry requirements are met, ???? ????????? ??????? ????? ??? ????????? ?????????? ?????????
Council, 2011). Once the experiment is complete, findings will work towards the treatment, 
prevention, and/or cure to the disease in humans. The final step of this type of experiment seems 
to be often overlooked by the public: when the results are successful, it might not only benefit 
human welfare, but might benefit the animal?s welfare too. The same treatment may one day be 
used to cure an animal with the same disease. Because of this cycle, in the long run, it is not 
humans being selfishly cruel to helpless creatures below them in the levels of creation, as it is 
frequently perceived. The animals have nearly the same probability of benefitting from the study 
as humans do.  
 In the opinion of the author, transpharmers, xenotransplanters, and food sources fall into 
the same category, ethically speaking. Agreeing with Mepham in his review, these applications 
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create animals as tools (Mepham, 1994). It is believed that each type of transgenic animal is 
created in good nature, though, and has the potential to be very helpful to the world. Approval by 
the FDA could lead to improved medical care, increased organs for transplant, and increased 
food for starving people in third world countries. Since each of these modifications could 
directly affect the humans involved and the environment, it is crucial that scientists aim to 
perfect the technology in a way that will not create pain for the animal as a result. Unfortunately, 
both xenotransplanters and food sources require the eventual death of the animal. However, the 
animal was bred to do so, and this debate is not specific to transgenic animals but also applies to 
the millions of animals sacrificed daily for human consumption. Some groups may believe this is 
selfish of humans to create animals to only benefit themselves. The author could argue that 
raising animals to be domesticated is also selfish when animals were put on this Earth to roam 
and be free in the wild. The fact that these transgenic animals are consumer products also 
contributes to a similar defense to that of disease models. Animals eat, have organs and need 
medicine to feel better when sick. As the technology grows, the findings can be applied to 
multiple species?????????????????????????????????????????????????????????????????????? ???????????
pig. 
 On an entirely different note, biological models are not as easy to defend. Thoughts 
???????????????????????????????????????????????? ??????????????? ??? ??? ?????????? ?????uld be nice to 
understand how each gene in the human body works, but the author believes it would be more 
beneficial to focus transgenesis on known diseases and conditions. The only benefit to such 
study lies in the futuristic opinion. If we study the knockin and knockout results of each gene, 
doctors could predict the conditions someone may develop throughout their lifetime, and thus 
give advice on how to prevent it from occurring. Because of this, scientific models should not be 
 49 
abandoned, but delayed. It may be more widely accepted if investigators work to try and solve 
the health problems of today instead of jumping into entirely unknown territory. 
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C H APT E R-4 
T R A NSG E NI C L E G A L I T I ES 
 
 Controversial technologies need laws regulating the use of those technologies. 
Transgenic technology versus conventional technology is one of five comparisons involved with 
analyzing ?????????? ??? ????? ???????????? ???? ???? ???????? are treated as though they are related 
topics, and it must be realized that any knowledge that pertains to one of them also applies to the 
other, and each is dependent on rules and procedures as well as the people involved with them. 
Since there are several different branches of transgenic technology, evaluation of the laws must 
also be looked at in reference to environmental health and human health (Chen, 2008).  
 To start understanding the laws needed to regulate transgenic animals, one must first 
distinguish the definition of the ????? ????????????????? ??? ???? ??????? ??? ?????? ???? ?????? ??? ???
industry that create and market things through manipulation of life forms and/or the use of 
knowledge of living organisms. Other times, biotechnology is the sole use of new technologies to 
modify plants and animals. From here, regulations must decipher between the ownership and use 
of such technologies. In the U.S., granting ownership of biotechnology is a responsibility of the 
Patent and Trademark Office (PTO), while the Environmental Agency, Department of 
Agriculture and the Food and Drug Administration (FDA) control the use of biotechnology 
jointly (Chen, 2008). The larger issue among transgenic animals, however, is the question of 
whether or not life should be patented. 
 
Animal Welfare Regulation 
 
Although it took until 2009 before the FDA rules were finalized for the use of transgenic 
???????????????????????????????????????????????????????????????????????????????????????????
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?????????????????????????????????????????????????????????????????????????????????????????????????
used for research if they have been personal pets, and any animals used for research must be 
provided with humane care (US Congress, 1966). Currently, the act is used as the minimum 
standard accepted for animals used in research, exhibition, transport, and dealing (U.S. Dept. of 
Agriculture, 2012).   
Since the formation of this law, multiple organizations have been created to ensure that 
all animal facilities treat animals humanely. One group, for instance, the Office of Laboratory 
Animal Welfare (OLAW), is a part of the National Institutes of Health (NIH). Aiming to provide 
?????????????????????????????????????????????????????????????????????????????????????????lations 
on humane care and use of animals (OLAW, 2005). Also working with OLAW and NIH is the 
Institutional Animal Care and Use Committee (IACUC), which is established at each laboratory. 
These committees are in charge of overseeing and evaluating the inst???????????????????????????
(IACUC, 2005). The IACUC works with scientists, institutional officials, and the attending 
veterinarian to ensure humane animal use and regulatory compliance of all animal research 
performed at that institution.  They also confirm and enforce policies, procedures, and the overall 
animal care program for the species present at that site. Guidelines are created to determine 
humane endpoints of studies, alternative studies using in vitro models or fewer animals, and 
appropriate veter?????? ?????? ?? ?????? ???? ???????? ???????? ?????????? ?????????? ??? ?????? ?????
???????????? ????????? ???????????????????? ??? ??? ?????????????????? ???? ???????????? ??? ????????????????
that the animal study is not currently being done elsewhere and has never been done before. 
Once that is determined, the model must be checked to ensure that no other in vitro experiment 
can be done to receive the same information (i.e. the proposed experiment ???????????????????????
Refine refers to modifying husbandry and experimental procedures to decrease pain and distress 
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????????????????????????????????????????????????????????????????????????????????????????????????
study by obtaining more information from fewer animals while not increasing pain or stress 
?????????????????????????????????????????????????????????????????????????????????????????????????????
welfare are being considered.  
 
T ransgenic Regulations 
 
 After nearly a decade of review, in 2009, the U.S. Food and Drug Administration (FDA) 
released the guidance they plan to use to regulate genetically engineered animals. The basis of 
these rules considers animals as drugs under the New Animal Drug provisions of the Federal 
Food, Drug, and Cosmetic Act (FFDCA), but are not legally binding (Wadman, 2008; FDA.gov, 
2009). The section of the FFDCA concerning new animal drugs outlines laws saying that the 
secretary has responsibility for determining if the new animal drug can be deemed safe, and if 
not, he has the ability to propose levels that can be considered safe or prohibit use. Tolerance 
levels are based on similar criteria used for food safety.  In this law, one can also find regulations 
on filing an application for the use and manufacturing of the new animal drug (U.S. Congress, 
2006). The FDA guidance goes as far as addressing environmental safety by controlling shipping 
and labeling of the animals, as well as requiring authorization for edible products from 
genetically engineered animals to enter food supplies. The FDA must also have knowledge of the 
characterization of the animals and manufacturing processes used with the animals. Once 
approved, the institution is responsible for recordkeeping and ensuring compliance by submitting 
annual reports and supplements with any changes in the investigation. In addition to these 
regulations, institutional guidelines and National Institutes of Health (NIH) guidelines must also 
be considered (FDA.gov, 2009). NIH guidelines cover topics such as human health and safety, 
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environmental safety, confinement used at the laboratory, and the roles of people at each 
institution (National Institutes of Health, 2011).  
 
Introduction to Patent Laws 
 
 The original patent laws date back to 1790. Currently, the patent law specifies how 
patents may be gained and any conditions involved with such. However, the US Constitution 
states that Congress has the ability to grant authors and inventors the right to secure writings and 
discoveries for a limited time period.  By law, a patent can be issued to any person who creates a 
??????????????????????????????????????????????????????????????????????????????????????????????
???????????? ??????? ?? ????????????? ??????????? ??????? ?????????????????????? ?????. As a 
part of the FFDCA, approved patents for new animal drugs can be filed with the request 
application used for claiming a use of the drug and protecting the applicant from patent 
infringement (U.S. Congress, 2006). Patent infringement law states specifically that submitting 
such application covers only new animal drugs manufactured by recombinant DNA and other 
genetic manipulation techniques (U.S. Patent and Trademark Office, 2007).  
 ????????????????????????????????????????????????????????????????????????????????????????????
Europe for instance, ????? ????? ????????? ???????? ???? ??? ???????????? ?????? ???? ???????????? ???
?????????????????????????????????????????????????????????????????????????????????????????????????
patent law has a section stating that patents cannot ???????????????????????????????????offensive 
????????????????????????????????????????????????????????????????????????????????????????????????
????????? ??????? ??????????? ????? ??????? ?????? ????????? ??????? ???????? ??????? ????? ???? ?????
???????? ??? ?????????? ???? ?????????? ????? ??? ?????? ???? ??????? but may not be considered 
??????????? ???????? ??????? ??????? ????? ??????? ???????????? ???????? ???? ??? ????? ????? ?????????
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inventions believed to be useful, novel, and inventive, however, humans are specifically not 
included under the law (Australia Patents Act, 1990).  
 
Oncomouse Patents: United States, Canada, & Europe 
 
 In 1980, the first patented living organism in the U.S. was a microbe designed to eat oil 
slicks. However, the Patent and Trademark Office did not originally give Chakrabarty the patent. 
After denial, the Supreme Court took up the case for judicial review (Jozwiak, 1994). The 
outcome of the case, Diamond v. Chakrabarty, awarded the investigator the patent because it 
was not ??????????? ??????????? to have microbes with such genetic make-up and Congress had 
intended for patent law to consist of everything made by man, and it was considered ?????????thus 
satisfying the usefulness requirement (Jozwiak, 1994; Diamond v. Chakrabarty, 1980; Council 
for Responsible Genetics, 2000). Since that court case, ????????????????????-naturally occurring, 
non-???????????????????? ??????? ??????????? ???? ??????? ?? ????????? ???? ????????? ???????? ??? ????
??????????????????????????s 1980 case was a breakthrough for transgenic technology applied to 
higher organisms, such as animals.  
In 1988, the U.S. PTO awarded first patented animal, the Havard-Dupont mouse, an 
oncomouse (Council for Responsible Genetics, 2000). This mouse has since been considered for 
patenting throughout the world. The United States currently has three patents awarded to the 
mouse created by Philip Leder and Timothy Stewart, researchers at Harvard Medical School. All 
three patents do not include humans to avoid moral and legal concerns regarding alteration of the 
human genome (WIPO Magazine, 2006). The first patent on the oncomouse (Leder et al., 1984) 
???????????????????????????????????????-human eukaryotic animal whose germ cells and somatic 
cells contain an activated oncogene sequence introduced into the animal, or an ancestor of the 
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animal, at an embryon??? ???????????? ??????? ??? ???? ??????? ????? ???????? ???? ??????????? ???????
region, the location of the transgene location (different from the site of the endogenous region), 
an inducible promoter sequence, a c-myc gene, various viral promoters and the fact that the 
animal is a mouse (Leder and Stewart, 1984). Years later, in 1992, Leder and Stewart filed 
another patent for the same oncomouse. This time the patent included the method for creating a 
cell culture from the somatic cells of the oncomouse (Leder and Stewart, 1992). Moving 
forward, the most recent U.S. patent for the oncomouse was given in 1999. It incorporated a 
method for testing suspected carcinogens and the method for testing treatment for any induced 
tumors (Leder and Stewart, 1999). Since transgenic technology was still fairly new at the time of 
the original 1984 oncomouse patent filing, questions arose about the patentability of animals. 
Mainly, should high-order mammals be patented, and how should moral implications be 
handled? As a result, there have been different responses to the subject in different countries 
(WIPO Magazine, 2006).  
 Although Europe approved the original oncomouse, the patent, once awarded, was 
limited to mice (WIPO Magazine, 2006). Like the first patented microbe, the oncomouse was not 
originally approved in Europe. After discussion, the Technical Board of Appeals of the European 
Patent Office (EPO) reversed their decision. They believed in the end that the detriments of the 
model were outweighed by the benefits it provided to the human species. Since then, the EPO 
has decided that animal patents shall be decided on a case-by-case basis (Jozwiak, 1994). 
Canada, on the other hand, concluded in 2002 that only the techniques that are used to create the 
mouse are patentable. The Canadian Supreme Court ruled that the transgenic mouse is not, by 
???????????? ?? ????? ???? ??????? ????? ????????? ????????? ????????????? ??? ???????????? ??? ????????
???????????????? ???????????? ???????????? ????? ???? ???????????????????????????????????????????-
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living process, ??????????????????????????????referred to ingredients mixed together by a person. 
Since the original Canadian Patent Act of 1869 did not include mammals or higher life forms, it 
had been decided that further debate was necessary to address moral and social issues (WIPO 
Magazine, 2006). 
 
Opponents to Patenting H igher L ife Forms 
 
 ??????????????? ????? ?????? ???? ???? ????????????? ????????? ???????? ??????????? ??????? ??????
some people have developed negative, disapproving views towards animal patents. One group, 
Council for Responsible Genetics, has expressed an opposition to animal patents in general, 
whether they be naturally occurring or engineered. They state nobody should be able to claim 
ownership over another living organism. Primary reasons for this include accessibility, cost and 
secrecy issues. However, they also mention that allowing patents will promote a decrease in 
genetic diversity, creating agricultural policies that are difficult to enforce and support. Their 
final argument focused on the morality, questioning: if genetically altered DNA in an animal is 
patentable where do human reproductive cells lie in this scheme (Council for Responsible 
Genetics, 2000)?  In addition to this, groups such as the American Anti-Vivisection Society 
argues that patenting animals conflicts with laws encouraging replacement experimental 
procedures (as described earlier in the chapter; Letterman, 2007). 
 Animal rights activists and small farmers are also among the people who are against the 
concept of patenting animals. The activists are concerned that patents will encourage inflicting 
disease upon the animals. Farmers, on the other hand, are afraid that the patents will hurt their 
business. They are under the impression that licensing fees will increase the cost in purchasing 
the transgenic animals from large biotechnology companies, while increased productivity will 
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cause the farmers to become dependent on purchasing the animals, thus hurting their budget 
(Jozwiak, 1994). 
 On a much larger scale than individual farmers or small organizations, Elisabeth Jozwiak 
mentions in her review the reasons entire countries deny patents. Often, the countries that do not 
allow patents are the lesser-developed countries (LCDs) of the world. Their argument is that by 
restricting patents, their own industries will be promoted which will ensure providing low cost 
products to their citizens. Also, similarly to Council for Responsible Genetics, LCDs believe that 
patents promote secrecy and any knowledge should be shared publically. In order to avoid 
patenting, LCDs require compulsory licensing that allows piracy and selling patented items at a 
much lower cost (Jozwiak, 1994). 
 
Benefits to Patenting T ransgenic Animals 
 
Despite large opposition towards patenting higher life forms, there are several large 
????????? ????? ???? ?????? ???????????? ??? ?????? ??? ?????????? ????????? ???? ????? ???????? ????? ?????
developing countries. Transgenic technology provides ways to increase food production, produce 
life-saving drugs, and increase knowledge of medical concepts. If these ideas are patented, then 
the patenting countries will have a higher likeliness of having that animal available mostly to 
them. Not only will people from developing countries be more likely to make their invention 
available to the LDC because they will not be afraid of piracy and fraud, but the cost of the 
patented items will decrease if they obey adequate patent laws (Jozwiak, 1994). 
This could help solve the problems with starving and sick people on multiple levels. If 
pharmaceuticals are produced by the transgenic animals, developed countries can make a profit 
from selling these animals to lesser countries by investing. In the end, the pharmaceutical 
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industry will grow and increase drug availability in countries in need of it. Likewise, food 
production and medical research will also be promoted. Another benefit to patenting food 
production and disease models is the overall health of these lesser-developed countries will 
become better as a result, even if those countries do not hold the patent. This lies in the fact that 
transgenic food sources are created to increase nutritional value and prevent the animals from 
developing diseases. The disease models will increase understanding of said diseases, making it 
more likely for doctors to diagnose and properly treat sick people  (Jozwiak, 1994). 
  
Disadvantages of Patenting Animals 
  
 The large issues that arise with the debate of patenting higher-life forms, such as 
mammals, are ethical considerations, especially those issues that remain unchanged with or 
without a patent. For instance, religious people argue that transgenic animals disrespect God, 
reduce the value of life, and encourages people to put money before traditional values. Generally 
speaking, people arguing against animal patents also overlook that humans have been owners of 
animals as pets for centuries (Jozwiak, 1994). Patent protection is also called intellectual 
property, thus showing that patents should be n???????????????????????????????????????????????? 
Economic issues and the regulation of patented animals must also be considered. The 
problem here lies in the fact that the subject areas are too broad to predict any issues that could 
potentially arise. There is no single statute that regulates all uses of genetically altered animals. 
Economically speaking, commercial production is most likely to increase in the agricultural 
transgenic applications such as food production and transpharmers. Even among the food 
production industry, there is a wide range of economic relationships. Within the dairy market, 
federal price supports are very important, while poultry is more competitive. This shows that 
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intellectual property issues associated with animal patenting could cause different problems, 
even if inside one ??????????????????? ??????????????????????? 
 
????????? ???????????????????????? 
 
 ???????? ??? ????? ??? ???? ???????? conclusions in the previous chapter, there are more 
benefits to patenting of animals than disadvantages. Although patenting has a negative 
connotation when including higher life forms, patenting animals is seen as no different from 
owning a pet. The only reason there is a difference is because most patents are associated with 
inanimate objects, and animal rights activists find that demeaning to the animal. As long as 
worldwide issues, such as piracy in lesser-developed countries, do not interfere, patenting has the 
potential to promote the use of transgenic animals. Knowledge and resources involved with the 
health and well being of people will then become more available to all people in need, thus 
improving health worldwide. 
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PR OJE C T C O N C L USI O NS 
 
 Transgenic technology has evolved to allow genetically manipulated animals to possess a 
?????????????????????????????????? not normally possessed by that particular species. The gene in 
question is typically incorporated into a cloning vector possessing regulatory sequences of DNA 
to help control which tissues the transgene is expressed. The transgene can be inserted to the 
????????? ??????? ???? ???? main techniques: pronuclear microinjection or introduction into 
embryonic stem (ES) cells. Pronuclear microinjection involves injecting a solution containing the 
transgene that will randomly integrate itself into the ?????????genome. ES cell manipulation, on 
the other hand, allows the use of homologous recombination, so the transgene will insert into a 
known gene locus, replacing the endogenous gene entirely. However, even with gene targeted 
integration, there is still a possibility that the transgene can insert into spots that either inactivate 
the transgene, or create an animal with a mutation. Since both ways can result in an incorporation 
that could harm the animal, the ethical considerations and legalities must be looked at carefully 
and individually for each application. Currently, transgenic animals are created to aid our 
analysis of disease pathways and treatments for diseases, food production, drug production, 
organs that can be transplanted into other species, and observation of biological processes.  
 By creating a genetically altered animal to suit man, many different debates arise 
involving animal welfare, effects on the environment, public safety, and laws that regulate the 
ownership and use of the animal. Following performing the research for this project, the author?? 
conclusion is that, overall, the advantages of transgenic technology outweigh the disadvantages, 
as long as there are proper committees and legislative oversights to regulate and enforce the rules 
for proper animal care. Animals should be humanely treated, and experiments should be altered 
to use as few animals as possible.  Since the animals are bred in captivity they are not meant to 
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be released into the wild, and even if they were it would not be likely that they would survive. 
However, experiments should be designed to have minimal environmental effects.  
In the long run, transgenic technology can benefit both humans and animals. Knowledge 
of disease pathways and biological processes has the ability to contribute to possible disease 
prevention and cures in humans and animals. Drug production can contribute to creating 
affordable medical care for people who need it. Likewise, food production can help the food 
shortage in places with starving people, and xenotransplanters can help solve the severe organ 
shortage problem. Because of these benefits, patenting the transgenic animals can be 
advantageous. Patents can increa????????????????????????????????????????????????????????????????
welfare by promoting the use of this technology by allowing the labs who created the animals in 
the first place to re-claim some of the money it took to make them. The knowledge gained 
through transgenesis can help ?????????????????????????????????, and doctors will be better able 
to diagnose problems and will have access to drugs necessary for treating the diseases. 
 
 
  
